Select region:

Clinical trials located in

Siena

Siena city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Siena, nestled in Italy’s Tuscany region, is renowned for its medieval brick buildings and the fan-shaped Piazza del Campo, the site of the famous Palio horse race held twice a year. The city’s 13th-century public square is dominated by the striking Gothic Palazzo Pubblico and its tower, Torre del Mangia. Siena’s historic center is a UNESCO World Heritage Site, a testament to its preserved Gothic architecture and significant cultural heritage. The city also houses the Siena Cathedral, an exquisite example of Italian Romanesque-Gothic architecture.

  • CT-EU-00033046

    Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    AustriaBelgiumCzechiaFranceGermanyItalyPolandPortugalSpain
  • Comparing new and standard treatments for non-small cell lung cancer

    This clinical trial compares novel treatment regimens against the standard of care in people with advanced non-small cell lung cancer (NSCLC). It’s divided into two parts: the first part focuses on safety and early response of new treatments. The second part compares the effectiveness and safety of these novel treatments with standard therapy. The trial includes drugs like docetaxel, feladilimab, ipilimumab, and others, evaluating their impact on cancer progression and patient survival. This study is significant for those seeking alternative treatments for advanced NSCLC.

    FranceGermanyItalySpain
  • Testing selinexor for relapsed large B-Cell lymphoma

    This clinical trial is about testing a drug called Selinexor on patients who have a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL) that has returned or hasn’t responded to treatment. Lymphoma is a type of cancer that starts in cells that are part of the body’s immune system. The trial is divided into two parts. In Part 1, the researchers will give 130 patients a 60mg dose of this drug to see how they respond. These patients have no other treatment options. In Part 2, the researchers will divide about 110 patients into two groups. One group will receive a 40mg dose and the other a 60mg dose. All the patients will be closely monitored until their disease progresses. The results of the study will be based on international guidelines and standards for assessing lymphoma.

    GreeceItalyPoland
  • Investigating new treatment method for specific head and neck squamous cell carcinoma

    This clinical trial is focused on evaluating the safety and efficacy of a new treatment for patients with a specific type of head and neck cancer caused by Human Papilloma Virus 16 (HPV16) and characterized by the presence of the PD-L1 protein. The treatment involves a combination of a novel drug, BNT113, and a known drug, pembrolizumab. The primary objective is to determine whether this combination is more effective than pembrolizumab alone in assisting the body’s immune system in fighting the cancer. The trial is divided into two parts. In the initial phase, the focus is on assessing the safety of the new drug combination. Subsequently, in the second phase, patients will be randomly assigned to receive either the new combination or pembrolizumab alone. The trial aims to compare the outcomes of the two groups, evaluating tumor response (whether tumors shrink, remain the same, or grow) and monitoring any potential side effects resulting from the treatment.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalSpainSwedenUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Study on Aticaprant’s safety and effects as an adjunctive therapy for major depressive disorder

    This trial is for adults and elders who are struggling with major depressive disorder (MDD). The trial involves a medicine called aticaprant, and this is supposed to be taken alongside what they are already using to handle their depression (SSRI or SNRI drugs). The study aims to determine the long-term safety and efficacy of aticaprant. To achieve this, close monitoring of adverse events, which includes negative reactions or changes in patients’ health, is crucial. Physical health indicators, such as weight, core body temperature, heart rate, and blood pressure, will be assessed to understand the potential impact of aticaprant. Additionally, the study will evaluate patients’ thoughts on suicide, any discernible changes in their sexual health, and their overall mood.

    BelgiumBulgariaCzechiaFranceHungaryItalyPolandSlovakiaSpainSweden
  • Study on customized therapy for advanced solid tumors

    The research study, now in its second phase, aims to examine if particular treatments, or treatment combinations, are safe and useful in treating certain hard-to-remove or spreading tumors. These treatments are personalized, chosen depending on certain genetic changes detected in a person’s tumor. It will take about 4 weeks to see if the treatment is successful. As part of the study, patients will have to answer some questions about their physical, emotional, mental, and social health, which will help paint a clear picture of their overall quality of life. Lastly, any negative impacts causes by the treatment are taken note of and classified according to their severity.

    BelgiumDenmarkFranceGermanyItalyPolandSpainUnited Kingdom
  • Study of nivolumab + relatlimab for new advanced melanoma cases

    The study explores the effects of combining Nivolumab and Relatlimab, given subcutaneously, in treating melanoma that hasn’t been treated before and can’t be surgically removed. The focus is on the medication levels in the blood and comparing the treatment’s impact on the disease with standard methods​​.

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    BelgiumFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    AustriaBelgiumFranceGermanyItalyNetherlandsSpainSwedenUnited Kingdom
  • Evaluating different drugs for advanced multiple myeloma

    This study is conducted to see how good a medication called Elranatamab is for individuals having multiple myeloma, a blood cancer that affects the marrow inside your bones. This study will use Elranatamab alone, or pair it with another medication called Daratumumab. The aim is to see if Elranatamab alone or mixed with Daratumumab is better than the current treatment of Daratumumab mixed with two other medications named Pomalidomide and Dexamethasone. This research is primarily for individuals who have undergone previous treatments with medications, Lenalidomide and a proteasome inhibitor. The study has two parts. The aim of the first part is the safety test and effects of Elranatamab mixed with Daratumumab at various doses. The second part will divide participants into three groups: Elranatamab alone, Elranatamab with Daratumumab, or the current treatment. The goal is to observe which treatment is safer and works better.

    AustriaCzechiaFranceGermanyGreeceItalyPolandSpainSwedenUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Testing new medication for advanced malignancies

    This study is about a new drug called INCA32459 in treating select advanced malignancies. The drug works by targeting two proteins, LAG-3 and PD-1, which are found in the body. The study has two parts. In the first part, different doses of the drug will be tested to see which one is most effective and safe. In the second part, the best dose identified in part 1 will be given to more patients. Researchers will continue to monitor the patients for side effects and will track how well the drug is working against the cancer.

    BelgiumFranceItalySpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNorwayPolandPortugalSpainSwedenUnited Kingdom
  • Research of combination therapy for metastatic melanoma

    This study looks into a new test treatment for serious skin cancer. It’s a big study, happening in multiple places. It will look at two things: one, a drug called HBI-8000 (Tudicdinostat) taken together with another drug called Nivolumab, and two, just Nivolumab on its own. The main goal is to see which approach works better for patients. Patients who can take part are ones who haven’t tried specific cancer treatments before (PD-1 or PD-L1 inhibitors). However, young people or people with quickly worsening brain tumors can’t take part. The patients are picked based on whether a certain substance is present in their cancer cells (PD-L1 expression) and the LDH level that’s found in their blood.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Examining Octaplex’s effect on stopping acute bleeding in patients on blood-thinning drugs

    This is a detailed study that aims to test the efficiency and safety of a medication called OCTAPLEX. The medication is used for patients who are having severe bleeding, and are already on a type of medication known as Factor Xa Inhibitor. Patients will be split into two groups and will receive the medication in either a high or low dosage. The study will observe the participants for 30 days to see how well their bodies are proceeding with preventing the bleeding. They will also be studying various health factors such as body temperature, pulse, breathing rate, and blood pressure.

    AustriaGermanyItalyPolandSpainUnited Kingdom
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in Italy:

.